Workflow
Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients
CGTXCognition Therapeutics(CGTX) Newsfilter·2024-07-29 11:00
  • CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration - - Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings - "The SHINE trial showed that after 182 days of treatment, CT1812 demonstrated evidence of clinical improvements ...